. Thus, it is important to enhance the therapeutic efficacy and reduce the neurological symptoms induced by HGGs, such as seizures, which significantly affect quality of life [3] . It is essential to identify patients at risk of developing a HGG-associated postoperative seizure such that better targeted therapies can be designed for controlling postoperative seizures and improving patient prognosis [4] .
Seizures are common in HGGs in the brain and are frequently an initial symptom of this deadly disease [5] [6] [7] . Seizures are common in diffuse gliomas, occurring in 50-90% of low-grade astrocytoma patients and in 20-50% of glioblastoma patients [8] . The pathogenesis of seizures induced by HGGs remains uncertain and most likely differs from that of LGGs. Seizures have been reported in 6% of patients with malignant glioma during the postoperative period [9, 10] . Thus, patients with brain tumours need to take antiepileptic drugs (AEDs) after neurosurgery. When uncontrolled, tumour-related epilepsy and antiepileptic drug toxicities substantially contribute to neurological morbidity and have a significant effect on the patients' quality of life (QOL) [11] [12] [13] [14] . Although epilepsy is more frequently observed in patients with LGGs, it is more difficult to control in patients with HGGs [15] . There is a vast difference between the pathogenesis of tumourrelated seizure and that of other types of seizure [16] . Although patients with HGGs experience symptomatic postoperative seizures, many patients do not experience postoperative seizures despite exhibiting similar histology and performance status. Thus, postoperative seizures cannot be entirely explained by tumourrelated or peritumoural factors. Instead, such seizures may result from a complex interaction between tumour-related and genetic factors [16] .
Despite the frequency of postoperative seizures, factors influencing seizures associated with HGGs have not been addressed in a detailed manner. Thus, the purpose of the present study was to identify the prognostic importance of postoperative seizures as well as predictors of seizure control after surgical resection. It is presently popular to investigate correlations between tumour-related biomarkers and surgical outcomes. Although previous studies [17] [18] [19] have identified some susceptibility candidate biomarkers associated with seizure control after surgery for LGGs, little is known regarding how the expression of these biomarkers may influence postoperative seizure in patients with HGGs. Here, we report our findings concerning postoperative seizure obtained from a large retrospective single-centre series of 147 patients with WHO grade III and IV gliomas with epileptic seizures prior to surgical treatment. In this analysis, we examined the prevalence and predictors of postoperative seizures and the prognostic significance of postoperative seizure on progressionfree survival and overall survival.
Methods

Patients
We retrospectively identified all patients with preoperative seizure who were 17 years of age or older; who demonstrated biopsy-proven anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic oligoastrocytoma (AOA), and glioblastoma multiforme (GBM) from the Chinese Glioma Genome Atlas (CGGA); and who underwent surgical resection at the Glioma Treatment Center of Beijing Tiantan Hospital from January 2006 to July 2013. Histological diagnosis was reaffirmed by two independent neuropathologists and graded according to the WHO classification. Cases with discrepancies were re-reviewed by another pathologist until a consensus was reached. Based on these criteria, we included a total of 147 patients. The clinical characteristics of the patients, which were systematically collected at the time of histopathological diagnosis from medical records, were the following: patient's age at diagnosis, sex, type of seizure (simple partial, complex partial and generalized seizures), tumour location, extent of resection, pathological examinations, and adjuvant therapy. The overall survival (OS) time, defined as the period from surgery to death, was collected when the patients visited the clinics and during phone interviews with the patients and/or their relatives. Progression-free survival (PFS) was defined as the time from surgery to image progression (appearance of a new lesion or 25% increase in tumour size).
The enrolment criteria included the following: age of at least 17 years, histologically confirmed anaplastic glioma or glioblastoma, occurrence of preoperative seizure and patient's consent. Patients who only underwent biopsy and those who were lost to follow-up or who had died of non-primary diseases were excluded. This study was approved by the Ethics Committee of Beijing Tiantan Hospital, and written informed consent was obtained from all of the patients.
Assessment and measurements of seizure outcome
The primary outcome variable was seizure status, which was evaluated after surgery using the Engel Classification of Seizures: class I = free of disabling seizures (completely seizure free; nondisabling, simple partial seizures only; some disabling seizures but free of disabling seizures for at least 2 years; generalized convulsion with AED withdrawal only); class II = rare disabling seizures (initially free of disabling seizures but rare seizures at the time of study; rare disabling seizures since surgery; more than rare disabling seizures but rare seizures for at least 2 years; nocturnal seizures only); class III = worthwhile improvement (worthwhile seizure reduction; prolonged seizure-free intervals amounting to more than half of the follow-up period but not less than 2 years); and class IV = no worthwhile improvement (no significant seizure reduction; no appreciable change; worse seizures). We divided the patients with preoperative seizure into two groups based on the epileptic outcome after surgery: 53 patients (36%) were completely seizure-free (Engel class I), whereas 94 patients (64%) experienced postoperative seizures (Engel classes II, III, and IV). The use of AEDs was based on the clinician's preference. All of the selected 147 patients experienced a preoperative seizure and took sodium valproate for seizure prophylaxis prior to surgery. After surgery, these patients typically continued AED treatment for 3-6 months and were gradually weaned off the medication. If the patients had any evidence of seizures, the AED treatment was continued.
Samples
Tumour tissue samples were obtained by surgical resection. Resected specimens were snap-frozen and stored in liquid nitrogen until DNA extraction or paraffin-embedding.
DNA extraction
The genomic DNA from frozen tumour tissues was isolated using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The DNA concentration and quality were measured using a NanoDrop ND-1000 spectrophotometer (Nano-Drop Technologies, Houston, TX, USA).
Molecular evaluations
All of the data from the CGGA (Chinese Glioma Genome Atlas) for which biomaterial was available were obtained. Immunohistochemistry staining was performed for seven routinely tested molecular markers. The IDH mutation status (pyro-sequencing for IDH1/2 mutation), MGMT promoter methylation (DNA pyrosequencing), and expression of Ki-67, EGFR, TP53, PTEN, and MGMT (immunohistochemistry) were assessed according to routine methods [16] . Because different molecular markers have different staining patterns and non-nuclear staining is generally stronger than nuclear staining, the cutoff points for dichotomization analyses were defined as follows: active immunohistochemical staining for TP53, Ki67, EGFR, and PTEN was represented using a scale of 0-3 (0-1 = low, 2-3 = high expression), and MGMT, which shows non-nuclear staining, was defined as 0-2 for low or 3 for high expression (Fig. 1) [3] .
Assessment of the extent of resection
The extent of resection was retrospectively classified from reports on MRIs performed either 3 months postoperative or less than 72 h after resection. Resection was defined as biopsy (<10% resection) or as partial (10-50%), subtotal (51-90%) or total (91-100%) resection. All of our selected patients had undergone more than 50% resection. Thus, we divided the patients into two groups: the subtotal resection group and the total resection group. All of the characteristics described above were assessed by an independent neuroradiologist who was blinded to the patient outcome.
Tumour location
The tumour location was considered the lobe or region of the brain within which the bulk of the glioma resided. These assignments were based on an evaluation of medical records and imaging study results, mainly MRI characteristics, including tumour side (left, right, or bilateral) and specific lobe involvement (frontal, temporal, parietal, occipital, and insula).
Follow-up
Survival data were collected by clinics during patient visits and/ or phone interviews. Patients who underwent biopsy only were not followed up at our centre and were subsequently excluded from the survival analysis.
Statistical analysis
All statistical analyses were performed using SPSS version 13.0 (SPSS, Chicago, IL, USA) and were tailored to address associations between the presence of preoperative seizures and clinicopathological characteristics and survival outcomes. Survival function curves were calculated using the Kaplan-Meier method, and differences were evaluated using the log-rank test. Univariate analyses were performed using the Chi-square test for dichotomous variables. All of the variables that were found to be associated with postoperative seizures through the Chi-square analysis (P < 0.05) were included in a backward stepwise logistic regression model. A probability value of 0.05 obtained after twosided P-values were computed was considered statistically significant.
Results
We identified patients with preoperative seizure who had undergone primary resection of cerebral high-grade glioma (HGGs) from 2006 to July 2013 from the CGGA database. Basic information of all of the included patients is included in Table 1 . We found 147 patients (age range, 17-76 years; median age, 43 years) with preoperative seizure who were at least 17 years of age and who had WHO grade III or IV tumours. Among these patients, 81 were male, and 66 were female. The patients were divided into two groups as follows: 72 and 75 patients with tumours with and without AO/AOA, respectively. In addition, 98 patients underwent radiotherapy, and 81 patients underwent chemotherapy. In our dataset, the percentage of patients accepting radiotherapy was only 67%. Although radiotherapy is a treatment applied for HGGs after surgery, the economic condition, equipment condition and patients' compliance can affect the number of patients who underwent radiotherapy after surgery. With regard to MRI characteristics, the most commonly involved lobe was the frontal (69%), followed by the temporal (38%), insula (19%), and parietal (11%) lobes. Forty-nine tumours were located in the left cerebral hemisphere, 54 were localized in the right cerebral hemisphere, and six were located bilaterally. According to their clinical symptoms, 76 (60%) patients exhibited secondary generalized seizures, 42 (33%) exhibited simple partial seizures, and nine (7%) Fig. 1 . Photomicrographs of tumour tissue with high and low levels of MGMT and EGFR expression, as detected through the staining intensity. demonstrated complex partial seizures. We excluded patients who were lost to follow up.
As shown in Fig. 1 , we selected four photomicrographs of tumour tissue stained for MGMT and EGFR with different scores. We selected seven biomarkers that may be connected with postoperative seizure. As shown in Fig. 2 , among patients with postoperative seizure, there were 20 (51%) patients with an IDH1 mutation, 17 (63%) with MGMT promoter methylation, eight (17%) patients with high EGFR expression, 17 (35%) patients with high TP53 expression, 19 (50%) patients with high PTEN expression, two (4%) patients with high MGMT expression, and 20 (41%) patients with high Ki-67 protein expression. -methylguanine DNAmethyltransferase protein expression; Ki67: a protein which in humans is encoded by the MKI67 gene; EGFRexp: epidermal growth factor receptor protein expression; TP53exp: a transcription factor protein which in humans is encoded by the TP53 gene; PTENexp: phosphatase and tensin homolog deleted on chromosome 10.
Seizure characteristics
To identify factors associated with postoperative seizure, we compared the demographic and tumour information between patients with and without seizure (see Table 1 for a complete list).
The Chi-square analysis revealed four variables that were significantly associated with the presence of seizures: AO/AOA (yes vs. no, P = 0.038, Chi-square test), EGFR expression (high expression vs. low expression, P = 0.0004), MGMT expression (high expression vs. low expression, P = 0.011), and PTEN expression (high expression vs. low expression, P = 0.045). The logistic regression analysis found that three out of the four variables were strongly associated with postoperative seizures: tumours with AO/AOA, low MGMT expression, and low EGFR expression were independent factors for a higher incidence of postoperative seizures (P-values, odds ratios, and 95% confidence intervals are shown in Table 2 ).
Prognostic value of postoperative seizures in high-grade gliomas
Of the 147 high-grade glioma patients (as shown in Fig. 3) , patients with postoperative seizures had a longer OS and PFS compared with those without seizures (median 837 days vs. 670 days and 482 days vs. 390 days), but this difference was not statistically significant (P = 0.275 and P = 0.146; Fig. 3 ). As shown in Table 3 , we found that the survival rate of patients with postoperative seizure was higher than that of those without postoperative seizure. With the passage of time, the survival rate of the two groups became closer in value.
Discussion
A total of 53 (36%) patients with postoperative seizure were included in our study, which is consistent with findings obtained in previous studies, whereas the cohort included 94 (64%) patients who did not suffer from postoperative seizure. In recent years, several prognostic variables have consistently been shown to be important in patients with GBM [20] . We assumed that the biological behaviour and the clinical factors of gliomas may, to some extent, be related to the presence of seizures. Thus, we retrospectively analysed a set of 147 patients with preoperative seizure to identify the clinical factors and biological behaviour associated with postoperative seizure and to assess the prognostic importance of postoperative seizure.
Seizure is common in patients with brain tumours and can substantially affect daily life, even if the tumour is under control [21] . The mechanisms underlying brain tumour-related epilepsy are most likely multifactorial because different biochemical and morphological changes in the peritumoural brain parenchyma are likely involved. The expansive growth of tumours can suppress peripheral tissues, which play an important role in the genesis of OS: overall survival; PFS: progress-free survival. seizures. Tumours can also secrete chemicals that change the tumour microenvironment [22] . It is well known that LGGs, which show expansive growth, can suppress peri-tissues more gravely than HGGs, which exhibit infiltrative growth. Thus, the incidence of seizures is higher in LGGs than HGGs.
It is also well established that seizures are more difficult to control in HGGs than in LGGs, but few studies on seizures in HGGs are available in the literature. There were three authoritative studies about epileptic seizures in LGGs. Comparatively speaking, the strength of this study lies in the following: (1) it has a novel research direction regarding seizures in HGGs; (2) the study focuses on the postoperative seizure control of 147 patients with preoperative seizure; (3) the study selected patients taking sodium valproate as an AED before surgery and subjected to the regular application of AED after surgery to eliminate drug interference; (4) data from CGGA were homogeneously collected; and (5) the study included multiple variables of interest, such as molecular markers.
The median age of the patients included in our study was 43 years. In contrast to other studies, age was not found to be a predictive factor for postoperative seizure control [4] . Consistent with our findings, Ozbek et al. showed that gender did not predict survival outcome (P = 0.429) [4] . There is no clear consensus concerning the extent of surgical resection in the current literature [4] . Miller et al. [23] suggested that the extent of surgery could predict seizure outcome. In their study, subtotal (P = 0.007) and total (P < 0.001) resections were found to serve as independent predictors of total epileptic seizure control after oncological treatment. Vecht et al. [24] and Shibamoto et al. [25] showed that extensive surgery was correlated with a longer survival time compared with limited surgery. However, in our study, we did not identify any difference in the postoperative seizure incidence between total resection and subtotal resection (P = 0.437). It is well known that the expansive growth of tumours can suppress peripheral tissues, which play an important role in the genesis of seizures. The total resection of tumours can relieve the suppression of tissues better than subtotal resection. However, our data showed that the subtotal resection mean removed 80% of the tumour location, indicating that subtotal resection exerted an effect on reducing pressure that was similar to that of total resection.
The findings obtained in previous studies are consistent with the results obtained in our study, demonstrating that oligodendroglial tumours are the most common tumour types that present with seizure [5] . Moreover, the logistic regression analysis revealed that AO/AOA can affect postoperative seizure control in an independent manner (P = 0.048).
The correlation between biomarkers and postoperative seizure has been one of the most popular research areas over the past two decades. Some predicted genetic and molecular tumour marker data have been published [18, 26] . Nevertheless, little is known regarding how changes in genetic and molecular expression can affect tumour-related postoperative seizure control. In our studies, seven routinely tested molecular markers were selected to predict the outcome of postoperative seizure control. We found that the MGMT methylation and IDH1 mutation could not predict the incidence of postoperative seizures (P = 0.685). These findings are in contrast to the results obtained in an earlier study by Yang et al., who found an association between the expression of Ki67 and the occurrence of preoperative seizure in grade III glioma [3] . However, we found that Ki67 could not predict postoperative seizure in grade III and IV tumours (P = 0.275). Moreover, consistent with the study conducted by Gan You, no association was found between tumour location and the incidence of postoperative seizure. However, for this seizure type, we could not identify an association with postoperative seizure. The Chi-square analysis revealed that the expression of EGFR, PTEN, and MGMT can predict the occurrence of postoperative seizure (P = 0.0004, P = 0.045, and P = 0.011, respectively). In addition, the logistic regression analysis found that only the expression of MGMT and EGFR was statistically significant (P = 0.05 and P = 0.001). Thus, patients with lower expression of MGMT and EGFR more frequently experienced postoperative seizures.
Another study conducted by Wang et al. [27] found that the GBMO (glioblastoma oligodendroglioma) group showed more frequent preoperative seizure occurrence, higher rates of IDH1 mutation, lower MGMT expression, and longer survival, supporting our hypothesis that AO/AOA may also increase the incidence of postoperative seizure.
LGGs are more strongly associated with seizures than HGGs. In conclusion, we found that the AO/AOA group was associated with an increased incidence of tumourrelated postoperative seizure.
The DNA repair protein MGMT, which is located on chromosome 10q26, is an important tumour-related biomarker [27] . We found a relationship between MGMT protein expression and factors associated with postoperative seizure. Previous studies have shown that tumours with lower MGMT protein expression are more sensitive to radiotherapy and chemotherapy and that GBM patients with lower MGMT protein expression lived longer lives [28] . Low MGMT protein expression is indicative of a more benign tumour. Previous studies have shown that benign tumours (expansive growth) are more associated with tumour-related seizures compared with malignant tumours (invasive growth). Thus, in this study, high MGMT protein expression may indicate that the tumours are more malignant and that these malignant tumours are less associated with tumour-related postoperative seizure.
EGFR is a tyrosine kinase that dimerises upon binding to extracellular EGF and mediates signal transduction. This signal elicits a downstream cascade via the mitogen-activated protein kinase/extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/Akt pathways, which generally promote growth and cell migration. Although such signalling is critical for normal organism development, glioma cells frequently use EGFR signalling to promote tumour behaviour. Gliomas employ several methods to upregulate EGFR signalling, including overexpression of the receptor via disrupted regulatory feedback, thereby sensitising the cell to extracellular EGF. Other methods include overexpression via EGFR gene amplification on 7p12 and generation of a truncation mutation, which produces a constitutively active EGFRvIII. The level of EGFR expression is dependent on the grade of the glioma. The level of EGFR expression in HGGs is also higher than that in LGGs. Thus, a tumour with high EGFR protein expression is more malignant, which may account for the low incidence of postoperative seizure in the HGGs with high EGFR protein expression. Thus, the difference in the expression profiles obtained between different grades likely accounts for this result [5] . The immunohistochemical (IHC) results obtained for MGMT and EGFR substantiate our results. High protein expression of MGMT and EGFR can make a tumour more malignant in different ways.
Despite medical and surgical advances, the prognosis of patients with HGG remains poor. Irradiation and chemotherapy are common treatments. However, our studies revealed no difference between postoperative seizure control and radiotherapy and chemotherapy. In summary, seizures are a major issue for patients with HGGs that significantly affects the patients' quality of life. This study found that high levels of MGMT and EGFR expression predispose patients to a favourable outcome in terms of postoperative seizure. Furthermore, the AO/ AOA group showed more frequent instance of postoperative seizures. Thus, the expression of MGMT and EGFR and tumours with AO/AOA provide insights into the development of effective treatment strategies aimed at predicting the prognosis of patients with HGGs.
